Our top pick for
Building a portfolio
Burning Rock Biotech Limited is a diagnostics & research business based in the US. Burning Rock Biotech shares (BNR) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||USD$18.64 - USD$39.75|
|50-day moving average||USD$31.55|
|200-day moving average||USD$27.82|
|Wall St. target price||USD$23.15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.48|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$66 million|
|Gross profit TTM||USD$313.9 million|
|Return on assets TTM||-14.68%|
|Return on equity TTM||-26.44%|
|Market capitalisation||USD$2.6 billion|
TTM: trailing 12 months
There are currently 935,234 Burning Rock Biotech shares held short by investors – that's known as Burning Rock Biotech's "short interest". This figure is 131.7% up from 403,558 last month.
There are a few different ways that this level of interest in shorting Burning Rock Biotech shares can be evaluated.
Burning Rock Biotech's "short interest ratio" (SIR) is the quantity of Burning Rock Biotech shares currently shorted divided by the average quantity of Burning Rock Biotech shares traded daily (recently around 423182.80542986). Burning Rock Biotech's SIR currently stands at 2.21. In other words for every 100,000 Burning Rock Biotech shares traded daily on the market, roughly 2210 shares are currently held short.
However Burning Rock Biotech's short interest can also be evaluated against the total number of Burning Rock Biotech shares, or, against the total number of tradable Burning Rock Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Burning Rock Biotech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Burning Rock Biotech shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Burning Rock Biotech shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Burning Rock Biotech.
Find out more about how you can short Burning Rock Biotech stock.
We're not expecting Burning Rock Biotech to pay a dividend over the next 12 months.
Burning Rock Biotech's shares were split on a 1:3 basis on 31 July 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Burning Rock Biotech shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Burning Rock Biotech shares which in turn could have impacted Burning Rock Biotech's share price.
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 13 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen Plus that targets therapy and immunotherapy, as well as immunotherapy- related biomarkers, such as microsatellite instability and tumor mutation burden, and NTRK fusions; and LungPlasma, a circulating tumor DNA liquid biopsy- based test for non-small cell lung cancer. It also offers ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with major pharmaceutical companies, including AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone Pharmaceuticals, and BeiGene primarily through central laboratory and companion diagnostics development services to pharmaceutical companies. The company was founded in 2014 and is headquartered in Guangzhou, China. .
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.